Duke Brain Tumor Immunotherapy Program,
Department of Neurosurgery,
Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery
Luis Sanchez-Perez has not added Biography.
If you are Luis Sanchez-Perez and would like to personalize this page please email our Author Liaison for assistance.
A simple method to cure established tumors by inflammatory killing of normal cells.
Nature biotechnology Sep, 2004 | Pubmed ID: 15300260
Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
Cancer research Mar, 2005 | Pubmed ID: 15753401
Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy.
Journal of immunology (Baltimore, Md. : 1950) May, 2005 | Pubmed ID: 15843579
Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells.
Nature medicine Oct, 2005 | Pubmed ID: 16170322
Killing of normal melanocytes, combined with heat shock protein 70 and CD40L expression, cures large established melanomas.
Journal of immunology (Baltimore, Md. : 1950) Sep, 2006 | Pubmed ID: 16951382
Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy.
Cancer research Jan, 2007 | Pubmed ID: 17210711
Toll-like receptors in tumor immunotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research Sep, 2007 | Pubmed ID: 17875756
Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer.
Cancer research Dec, 2007 | Pubmed ID: 18089828
Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology Oct, 2008 | Pubmed ID: 18587008
Type 17 CD8+ T cells display enhanced antitumor immunity.
Blood Jul, 2009 | Pubmed ID: 19471017
Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas.
Cancer research Oct, 2009 | Pubmed ID: 19738045
Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.
Proceedings of the National Academy of Sciences of the United States of America Oct, 2009 | Pubmed ID: 19805141
A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites.
Bone Jul, 2010 | Pubmed ID: 20233612
Research highlights.
Immunotherapy Nov, 2009 | Pubmed ID: 20635909
Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.
Cancer research Sep, 2010 | Pubmed ID: 20647327
Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.
Journal of immunotherapy (Hagerstown, Md. : 1997) May, 2011 | Pubmed ID: 21499127
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.
Blood Sep, 2011 | Pubmed ID: 21768296
Th17 cells are long lived and retain a stem cell-like molecular signature.
Immunity Dec, 2011 | Pubmed ID: 22177921
Immunotherapy with tumor vaccines for the treatment of malignant gliomas.
Current drug discovery technologies Dec, 2012 | Pubmed ID: 22339070
Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.
Proceedings of the National Academy of Sciences of the United States of America Jan, 2013 | Pubmed ID: 23248284
Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.
PloS one , 2013 | Pubmed ID: 23527092
BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.
Cancer immunology, immunotherapy : CII Jun, 2013 | Pubmed ID: 23591978
Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.
Journal of immunological methods Sep, 2013 | Pubmed ID: 23806556
Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia Jan, 2014 | Pubmed ID: 24054399
EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.
Clinical cancer research : an official journal of the American Association for Cancer Research Feb, 2014 | Pubmed ID: 24352643
Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody.
Oncoimmunology Dec, 2013 | Pubmed ID: 24475376
Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody.
Cancer immunology research Sep, 2013 | Pubmed ID: 24570975
EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
PloS one , 2014 | Pubmed ID: 24722266
Leveraging chemotherapy-induced lymphopenia to potentiate cancer immunotherapy.
Oncoimmunology , 2014 | Pubmed ID: 25610727
Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrence.
Oncoimmunology , 2014 | Pubmed ID: 25610729
关于 JoVE
版权所属 © 2024 MyJoVE 公司版权所有,本公司不涉及任何医疗业务和医疗服务。